Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

2023; Elsevier BV; Volume: 35; Issue: 1 Linguagem: Inglês

10.1016/j.annonc.2023.10.117

1569-8041

Antonio Passaro, Jing Wang, Yan Wang, S.-H. Lee, Barbara Melosky, Jin‐Yuan Shih, Jing Wang, K. Azuma, Óscar Juan, Manuel Cobo, Enriqueta Felip, Nicolas Girard, Alexis B. Cortot, Raffaele Califano, Federico Cappuzzo, Scott Owen, Sanjay Popat, Ju Le Tan, Jorge Salinas, Pascale Tomasini, Ryan D. Gentzler, William N. William, Karen L. Reckamp, Toshiaki Takahashi, Sandip Ganguly, Dariusz M. Kowalski, Alessandra Bearz, Melanie Mackean, P. Barala, Ariel B. Bourla, Angela Girvin, James Greger, Dawn Millington, M. Withelder, John Xie, Tao Sun, Shalin Shah, B. Diorio, R.E. Knoblauch, Joshua Bauml, Rosario García Campelo, Byoung Chul Cho,

Cancer therapeutics and mechanisms

Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial.